Aneurysm, Intracranial

3

Review clinical trials related to Aneurysm, Intracranial. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms

To determine safety and effectiveness of the p48 MW HPC and p64 MW HPC Flow Modulation Device in the treatment of wide-necked intracranial aneurysms.

Participants needed: 214
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: phenox Inc.Updated: Jun 25, 2026Locations: 21
Eligibility criteria

Subject is ≥ 18 years [+6]

Previous flow diverter or stent within the parent vessel of the target aneurysm... [+19]

Status: Recruiting

Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)

The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass Elite with Guardian Flow Diverter System (FDS) in the treatment of unruptured, wide-neck saccular or fusiform, intracranial aneurysms (IAs) located on the internal carotid artery (ICA) or its branches.

Participants needed: 183
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Stryker NeurovascularUpdated: Apr 8, 2026Locations: 10
Eligibility criteria

Age is ≥18 and ≤80 years at the time of consent [+5]

Has an extradural target aneurysm [+24]

Status: Recruiting

Pipeline Embolization for Intracranial Aneurysms

This study collected the clinical, laboratory, and imaging data from patients with intracranial aneurysms, who underwent Pipeline implantation. The purpose of this study is to observe the safety, effcacy, and haemodynamics after Pipeline embolization.

Participants needed: 1,000
Trial details
Age: 22-75Biological sex: AllType: ObservationalSponsor: Zhujiang HospitalUpdated: Nov 18, 2024Locations: 1Duration: 3 Years
Eligibility criteria

Aged 22 to 75 years old, male or non-pregnant female; [+5]

With contraindications to flow-diversion treatment or known allergy to cobalt-ch... [+8]